ALSO NOTED: What to expect from Pfizer's new CFO; BrainStorm plans stem cell trials; Phoenix biotech plans San Diego move; and

> Newtown, PA-based CollaGenex says that it has reaped positive data from a mid-stage study of Col-118 for the treatment of erythema. Release

> BrainStorm Cell Therapeutics says it's on track to become the first developer to win approval for clinical trials on a new Parkinson's therapy that uses adult stem cells extracted from the patient. Report

> Ribomed Biotechnologies says the loss of its Phoenix lab space is forcing a move to San Diego. Report

> Cephalon says it is buying the North American rights to Amrix, a muscle relaxing drug, from ECR Pharmaceuticals for $100 million. Report

> Clinical Data is building its biomarker business with the $11.84 million acquisition of Epidauros Biotechnologie. Release

> Nucryst Pharmaceuticals has named Thomas Gardner as chairman, president and CEO. Release

> Alltracel plans to buy Synpart, an oral care business. Report

> It might sound like a candidate for the So What? award, but the FDA's approval of the "atypical" antipsychotic Risperdal for use in children and adolescents is a landmark decision. Report

> As Frank D'Amelio takes over as Pfizer's financial fix-it guy, what changes are in store for the company? FiercePharma

And Finally… Scientists are deeply skeptical, but China's Beike Biotechnology has been touting miracle cures spurred by stem cell therapies that are still years away from approval in most other countries. Article